keyword
MENU ▼
Read by QxMD icon Read
search

Statins diabetes hba1c

keyword
https://www.readbyqxmd.com/read/29322605/declare-timi-58-participants-baseline-characteristics
#1
Itamar Raz, Ofri Mosenzon, Marc P Bonaca, Avivit Cahn, Eri T Kato, Michael G Silverman, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John Wilding, Ingrid Am Gause-Nilsson, Anna Maria Langkilde, Peter A Johansson, Marc S Sabatine, Stephen D Wiviott
BACKGROUND: Cardiovascular (CV) outcome trials with new glucose lowering agents (GLA) are designed to prove CV safety in high CV risk populations. However, the level of CV risk differs greatly among trials, which may influence comparability and generalizability of results. AIM: We describe baseline characteristics of participants randomized in the Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58) trial, the pivotal study to assess CV outcomes with dapagliflozin...
January 11, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29286954/selective-%C3%A3-1-blockers-are-not-associated-with-new-onset-diabetes-mellitus-in-hypertensive-patients
#2
Yoonjee Park, Byoung Geol Choi, Seung-Woon Rha, Man Jong Baek, Yang Gi Ryu, Se Yeon Choi, Jae Kyeong Byun, Min Suk Shim, Ahmed Mashaly, Hu Li, Won Young Jang, Woohyeun Kim, Jun Hyuk Kang, Jah Yeon Choi, Eun Jin Park, Sung Hun Park, Sunki Lee, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
BACKGROUND: Although ß-blockers are known to increase new-onset diabetes mellitus (DM), previous evidence have been controversial. It has been suggested that newer vasodilatory ß-blockers yield better glycemic control than older nonselective agents. The aim of this study was to evaluate the diabetogenicity of currently used newer ß-blockers based on ß1 receptor selectivity in a series of Asian population. METHODS: We investigated a total of 65,686 hypertensive patients without DM from 2004 to 2014...
January 2018: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/29246694/effects-of-diabetes-and-glycemia-control-on-risk-of-hepatocellular-carcinoma-after-seroclearance-of-hepatitis-b-surface-antigen
#3
Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan, Yee-Kit Tse, Alice Pik-Shan Kong, Kelvin Long-Yan Lam, Grace Chung-Yan Lui, Grace Lai-Hung Wong
BACKGROUND & AIMS: Diabetes is associated with a 2-fold increase in risk of hepatocellular carcinoma (HCC) among patients with chronic hepatitis B virus (HBV) infection. However, we know little about the effect of diabetes on HCC risk after seroclearance of hepatitis B surface antigen (HBsAg). We evaluated the effect of diabetes and glycemic control on HCC development after HBsAg seroclearance in a population-wide study in Hong Kong. METHODS: We performed a retrospective study of 4568 patients with chronic HBV infection who cleared HBsAg from January 2000 through August 2016, using the Clinical Data Analysis and Reporting System of the Hospital Authority, Hong Kong...
December 12, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29233102/the-gene-treatment-interaction-of-paraoxonase-1-gene-polymorphism-and-statin-therapy-on-insulin-secretion-in-japanese-patients-with-type-2-diabetes-fukuoka-diabetes-registry
#4
Akiko Sumi, Udai Nakamura, Masanori Iwase, Hiroki Fujii, Toshiaki Ohkuma, Hitoshi Ide, Tamaki Jodai-Kitamura, Yuji Komorita, Masahito Yoshinari, Yoichiro Hirakawa, Atsushi Hirano, Michiaki Kubo, Takanari Kitazono
BACKGROUND: Although statins deteriorate glucose metabolism, their glucose-lowering effects have emerged in some situations. Here, we assessed whether these effects are a consequence of statins' interaction with paraoxonase (PON)1 enzyme polymorphism. METHODS: Adult Japanese type 2 diabetes patients (n = 3798) were enrolled in a cross-sectional study. We used Q192R polymorphism of the PON1 gene as a representative single-nucleotide polymorphism and focused on the effects of the wild-type Q allele, in an additive manner...
December 12, 2017: BMC Medical Genetics
https://www.readbyqxmd.com/read/29217412/glucagon-like-peptide-1-receptor-agonists-reduced-the-low-density-lipoprotein-cholesterol-in-japanese-patients-with-type-ii-diabetes-mellitus-treated-with-statins
#5
Yukiko Hasegawa, Mika Hori, Tomoko Nakagami, Mariko Harada-Shiba, Yasuko Uchigata
BACKGROUND: Patients with type II diabetes mellitus (T2DM) often have hypercholesterolemia, and their serum low-density lipoprotein cholesterol (LDL-C) levels are not always well-controlled even by statin treatment. The glucose-lowering glucagon-like peptide-1 receptor agonists (GLP-1RAs) are reported to change the lipid profiles in T2DM patients, but their effects have been unclear. OBJECTIVE: We examined whether GLP-1RAs affect serum cholesterol levels in T2DM patients with/without statin treatment...
November 21, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29209815/portrait-of-women-with-type-1-or-type-2-diabetes-of-childbearing-age-attending-diabetes-clinics-in-italy-the-amd-annals-initiative
#6
Marina Scavini, Maria Chiara Rossi, Marco Scardapane, Antonio Nicolucci, Valeria Manicardi, Giuseppina Russo, Paolo Di Bartolo, Carlo B Giorda, Nicoletta Musacchio, Antonio Ceriello, Stefano Genovese, Chiara Molinari, Nicoletta Dozio
AIM: To describe characteristics relevant in case of an unplanned pregnancy for T1D or T2D women of childbearing age. METHODS: We analyzed the 2011 AMD-Annals dataset, compiling information from 300 clinics (28,840 T1D patients and 532,651 T2D patients). A risk score of unfavorable conditions for pregnancy included HbA1c > 8.0%; BMI ≥ 35; systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg; microalbuminuria/proteinuria; use of statins, ACE inhibitors, ARB; use of diabetes drugs other than metformin/insulin...
December 5, 2017: Acta Diabetologica
https://www.readbyqxmd.com/read/29191193/adequacy-of-control-of-cardiovascular-risk-factors-in-ambulatory-patients-with-type-2-diabetes-attending-diabetes-out-patients-clinic-at-a-county-hospital-kenya
#7
Mercy W Kimando, Frederick C F Otieno, Elijah N Ogola, Kenn Mutai
BACKGROUND: Type 2 diabetes is associated with substantial cardiovascular morbidity and mortality arising from the high prevalence of cardiovascular risk factors such as hypertension, dyslipidaemia, obesity, poor glycaemic control and albuminuria. Adequacy of control of these risk factors determines the frequency and outcome of cardiovascular events in the patients. Current clinical practice guidelines emphasize primary prevention of cardiovascular disease in type 2 diabetes. There is scarce data from the developing countries, Kenya included, on clinical care of patients with type 2 diabetes in the regions that are far away from tertiary health facilities...
December 1, 2017: BMC Endocrine Disorders
https://www.readbyqxmd.com/read/29180351/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitors-and-incident-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis-with-over-96-000-patient-years
#8
Luiz Sérgio F de Carvalho, Alessandra M Campos, Andrei C Sposito
OBJECTIVE: Like mutations with loss of function in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, inhibitors of PCSK9 (PCSK9i) may potentially favor the manifestation of diabetes. RESEARCH DESIGN AND METHODS: A meta-analysis of phase 2/3 randomized clinical trials (RCTs) assessed PCSK9i versus placebo in primary hypercholesterolemia setting. Statins and ezetimibe were used in 98.4% of these studies and balanced between PCSK9i and placebo. We calculated relative risks (RRs) and 95% CIs using random- and fixed-effect models...
November 27, 2017: Diabetes Care
https://www.readbyqxmd.com/read/29158710/the-impact-of-pharmacists-providing-direct-patient-care-as-members-of-interprofessional-teams-on-diabetes-management
#9
Osamah M Alfayez, Majed S Al Yami, Maryam T Fazel
The purpose of this study was to evaluate the impact of pharmacist providing direct patient care as a member of interprofessional team on diabetes management. This study is a retrospective chart review of diabetes patients seen by a pharmacist in an endocrinology clinic affiliated with an academic medical center. The following patient outcomes were recorded pre and post the pharmacist intervention: glycemic control as measured by change in hemoglobin A1c (HbA1c), change in systolic blood pressure (SBP) and diastolic blood pressure (DBP), statin use, and use of angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)...
November 2017: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://www.readbyqxmd.com/read/29158232/development-and-validation-of-qdiabetes-2018-risk-prediction-algorithm-to-estimate-future-risk-of-type-2-diabetes-cohort-study
#10
Julia Hippisley-Cox, Carol Coupland
Objectives To derive and validate updated QDiabetes-2018 prediction algorithms to estimate the 10 year risk of type 2 diabetes in men and women, taking account of potential new risk factors, and to compare their performance with current approaches.Design Prospective open cohort study.Setting Routinely collected data from 1457 general practices in England contributing to the QResearch database: 1094 were used to develop the scores and a separate set of 363 were used to validate the scores.Participants 11...
November 20, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/29155119/high-serum-bilirubin-is-associated-with-lower-prevalence-of-peripheral-arterial-disease-among-cardiac-patients
#11
Michishige Ozeki, Hideaki Morita, Masatoshi Miyamura, Tomohiro Fujisaka, Shu-Ichi Fujita, Takahide Ito, Kensaku Shibata, Suguru Tanaka, Koichi Sohmiya, Masaaki Hoshiga, Nobukazu Ishizaka
Several studies have shown that subjects with higher serum bilirubin may have a lower risk of cardiovascular disorders. We herein investigated whether serum bilirubin concentration is associated with lower extremity ischemia among cardiology patients. In total, 935 patients without a history of angioplasty or bypass surgery of the lower limb arteries and who had bilateral ankle-brachial index measurements were included in the study. Peripheral arterial disease (PAD) was defined to be present when ABI of either or both sides was <0...
November 18, 2017: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29154060/efficacy-and-safety-of-a-combination-of-red-yeast-rice-and-olive-extract-in-hypercholesterolemic-patients-with-and-without-statin-associated-myalgia
#12
Christian Tshongo Muhindo, Sylvie A Ahn, Michel F Rousseau, Yvan Dierckxsens, Michel P Hermans
Cholesfytol®, a lipid-lowering dietary supplement with antioxidant and anti-atherosclerotic properties, combines red yeast rice (RYR) and olive extract (5mg hydroxytyrosol equivalent) and represents an alternative for patients who do not wish or are unable to use chemical statins, including individuals with previous statin-associated muscle symptoms (SAMS). A 2-months observational non-randomized study was performed to evaluate the efficacy, tolerance and safety of Cholesfytol® (1 tablet/day) in 642 hypercholesterolemic patients (mean age: 59 yrs; total cholesterol (TC) ≥200; LDL-C ≥140mg/dl)...
December 2017: Complementary Therapies in Medicine
https://www.readbyqxmd.com/read/29134608/factors-that-may-account-for-cardiovascular-risk-reduction-with-a-dipeptidyl-peptidase-4-inhibitor-vildagliptin-in-young-patients-with-type-2-diabetes-mellitus
#13
Marc Evans, Plamen Kozlovski, Päivi M Paldánius, James E Foley, Vaishali Bhosekar, Carmen Serban, Angelo Avogaro
INTRODUCTION: In a meta-analysis, we observed a significant 37% relative risk reduction in prospectively adjudicated major adverse cardiac events [MACEs, comprising of non-fatal myocardial infarction, non-fatal stroke, cardiovascular (CV) death] with vildagliptin vs. comparators in younger (< 65 years) patients with type 2 diabetes mellitus (T2DM), while the risk was similar in older patients (≥ 65 years). We carried out an exploratory analysis to identify the patient characteristics and on-treatment effects that may have contributed to the different outcomes in the two age groups...
November 13, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29107453/longitudinal-trends-and-predictors-of-statin-use-among-patients-with-diabetes
#14
Meghan B Brennan, Elbert S Huang, Jennifer M Lobo, Hyojung Kang, Marylou Guihan, Anirban Basu, Min-Woong Sohn
AIM: Statins reduce morbidity and mortality among patients with diabetes, but their use remains suboptimal. Understanding trends in statin use may inform strategies for improvement. METHODS: We enrolled a national, retrospective cohort of 899,664 veterans aged≥40years with diabetes in 2003. We followed them through 2011, dividing the nine-year follow-up into 90-day periods. For each period, we determined statin use, defined as possession of ≥30-day supply. We examine factors associated with statin uptake among baseline non-users with a multivariate model...
September 25, 2017: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/28927706/cardiovascular-safety-and-efficacy-of-the-pcsk9-inhibitor-evolocumab-in-patients-with-and-without-diabetes-and-the-effect-of-evolocumab-on-glycaemia-and-risk-of-new-onset-diabetes-a-prespecified-analysis-of-the-fourier-randomised-controlled-trial
#15
Marc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, Robert P Giugliano, Prakash Deedwania, Gaetano M De Ferrari, Sabina A Murphy, Julia F Kuder, Ioanna Gouni-Berthold, Basil S Lewis, Yehuda Handelsman, Armando Lira Pineda, Narimon Honarpour, Anthony C Keech, Peter S Sever, Terje R Pedersen
BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this prespecified analysis of FOURIER, we investigated the efficacy and safety of evolocumab by diabetes status and the effect of evolocumab on glycaemia and risk of developing diabetes. METHODS: FOURIER was a randomised trial of evolocumab (140 mg every 2 weeks or 420 mg once per month) versus placebo in 27 564 patients with atherosclerotic disease who were on statin therapy, followed up for a median of 2·2 years...
December 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28913755/management-and-clinical-outcome-of-stable-coronary-artery-disease-in-austria-results-from-5%C3%A2-years-of-the-clarify-registry
#16
Irene M Lang, Roza Badr-Eslam, Nicola Greenlaw, Robin Young, Philippe Gabriel Steg
BACKGROUND: The population of patients with established coronary artery disease (CAD) is growing because of an improvement in outcomes and survival from acute disease episodes. Nevertheless, these patients remain at high risk of cardiovascular events. Thus, CAD management is important in prevention of disease progression. The objective of this analysis was to describe disease management and clinical outcome of Austrian outpatients with stable CAD over 5 years by using data from the international CLARIFY registry...
September 14, 2017: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/28893495/the-association-between-pulse-wave-velocity-and-peripheral-neuropathy-in-patients-with-type-2-diabetes-mellitus
#17
Anastasios Tentolouris, Ioanna Eleftheriadou, Pinelopi Grigoropoulou, Alexander Kokkinos, Gerasimos Siasos, Ioannis Ntanasis-Stathopoulos, Nikolaos Tentolouris
AIMS: Diabetic peripheral neuropathy (DPN) is the most common diabetic complication, affecting up to half of the patients with type 2 diabetes mellitus (T2DM). Increased aortic stiffness, measured with the carotid-femoral pulse wave velocity (PWV), has been associated with incidence of cardiovascular disease independently of traditional risk factors. Previous data showed associations between risk factors for macroangiopathy and DPN in diabetes. However, the association between PWV and DPN is not well known...
July 27, 2017: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/28830436/effects-of-background-statin-therapy-on-glycemic-response-and-cardiovascular-events-following-initiation-of-insulin-therapy-in-type-2-diabetes-a-large-uk-cohort-study
#18
Uchenna Anyanwagu, Jil Mamza, Richard Donnelly, Iskandar Idris
AIM: Statins may increase the risk of new-onset diabetes and adversely affect glycaemic control, but their effects on the glycemic response and mortality outcomes following commencement of insulin therapy in patients with Type 2 Diabetes (T2D) are unclear. METHODS: A retrospective cohort study was conducted in 12,725 insulin initiators with T2D using The Health Improvement Network (THIN) UK database. Changes in HbA1c at 6, 12, 24 and 36 months, and the 5-year risk of mortality and (3-point) major adverse cardiovascular events (MACE), were compared between prior users (n = 10,682) and non-users (n = 2043) of statin therapy who were newly commenced on insulin treatment...
August 22, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28815569/glucose-dependent-leucocyte-activation-in-familial-hypercholesterolemia
#19
Natasja Koks, Marijke A de Vries, Erwin Birnie, Arash Alipour, Manuel Castro Cabezas
BACKGROUND: Leucocyte activation is an obligatory factor in the development of atherosclerosis. The postprandial situation has been associated to increased leucocyte activation in several disorders, such as type 2 diabetes mellitus and familial combined hyperlipidaemia. Our study aim was to evaluate the effect of post-OGTT hyperglycaemia on leucocyte activation in patients with familial hypercholesterolemia (FH). MATERIALS AND METHODS: Patients who met the diagnostic criteria for heterozygous FH and healthy volunteers were asked to undergo an oral glucose tolerance test...
August 16, 2017: European Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28811859/long-term-effect-of-alogliptin-on-glycemic-control-in-japanese-patients-with-type-2-diabetes-a-3-5-year-observational-study
#20
Kohzo Takebayashi, Tatsuhiko Suzuki, Rika Naruse, Kenji Hara, Mariko Suetsugu, Takafumi Tsuchiya, Toshihiko Inukai
BACKGROUND: The goal of the current study was to investigate the long-term effects (after 3 years or more) of alogliptin on glycemic control in Japanese patients with type 2 diabetes. METHODS: We retrospectively studied the effect of alogliptin on glycemic control in the patients with type 2 diabetes who had participated in our previous 3-month study and who continued to take alogliptin for at least 36 months. RESULTS: The mean duration of alogliptin treatment was 42...
September 2017: Journal of Clinical Medicine Research
keyword
keyword
47350
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"